"With all of MorphoSys’ Phase 3 clinical programs now fully enrolled and additional cost optimization measures planned, MorphoSys’ anticipated 2024 operating expenses are expected to be lower compared to 2023. As a result, the company expects an anticipated 2024 cash burn of approximately € 250 million (excluding debt and interest payments).
Thanks for sharing that article jerry. Morphosys is a little further advanced in their programs that Patrys but it does illustrate the appetite by big pharma for acquisitions.
"With all of MorphoSys’ Phase 3 clinical programs now fully...
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 324608 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 324609 | 1 |
View Market Depth
| Last trade - 09.00am 05/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable